scanance.
Sign inGet Premium
CE

Certara, Inc.

CERTHealthcareNASDAQ

Health Information Services

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$418.8M
+8.7% YoY
Net Income
-$1.6M
+86.8% YoY
EBITDA
$102.5M
+41.7% YoY
Free Cash Flow
$116.6M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Certara, Inc.

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory. The $905.4M market capitalization puts CERT squarely in small-cap range for its industry. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.

Key stats
Market Cap$905.4M
Fwd P/E14.08
EPS$-0.10
Beta1.53
52W Change-47.1%
ROE-1.4%
Analysis

On the balance sheet, CERT has $149.5M in cash with $304.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $116.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -1.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $335.6M (2022) to $418.8M (2025), reflecting a 25% increase over the period.

Certara, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. No single metric tells the full story. Reviewing CERT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms